Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Biomarker Directed Adjuvant Chemotherapy for Resected Pancreas Cancer

NCT01411072 is registered in ClinicalTrials.gov with AHS Cancer Control Alberta as lead sponsor.

NCT NCT01411072
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01411072 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Biomarker Directed Adjuvant Chemotherapy for Resected Pancreas Cancer
Lead sponsor
AHS Cancer Control Alberta
Phase
Not applicable
Overall status
Unknown status
Start date
September 30, 2011
Completion date
December 31, 2015
Enrollment
20 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pancreas cancer